“…Despite their similarities as cholinesterase inhibitors, chlorpyrifos and diazinon differ in their propensity to elicit oxidative stress [31,40,41] and therefore could have different effects on PD-related endpoints. For our evaluations, we used PC12 cells, a classical in vitro model for neuronal development [52] that has already been validated to reproduce the mechanisms and outcomes found after in vivo organophosphate exposures [26,27,38,39,41,42,46,47,51]. We evaluated gene expression patterns with cDNA microarrays, using a planned comparisons approach that focused on the relevant PD-related genes, rather than performing a blanket evaluation of the entire transcriptome [40,43,45–47].…”